{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:19:40Z","timestamp":1774984780562,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.ejps.2005.04.017","type":"journal-article","created":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T11:46:32Z","timestamp":1118403992000},"page":"26-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2\u2032-O-methyl phosphodiester oligonucleotides in normal rats"],"prefix":"10.1016","volume":"26","author":[{"given":"Gabor","family":"Lendvai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Velikyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Laryea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"V\u00e4lil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Salom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"L\u00e5ngstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Roivainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2005.04.017_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000076139","article-title":"Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells","volume":"24","author":"Abaza","year":"2003","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ejps.2005.04.017_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0163-7258(97)00108-3","article-title":"Perspectives in antisense therapeutics","volume":"76","author":"Agrawal","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2005.04.017_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/oli.1.1997.7.575","article-title":"Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats","volume":"7","author":"Agrawal","year":"1997","journal-title":"Antisense Nucleic Acid Drug. Dev."},{"key":"10.1016\/j.ejps.2005.04.017_bib4","first-page":"468","article-title":"Gene therapy for the treatment of AIDS: animal models and human clinical experience","volume":"4","author":"Amado","year":"1999","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejps.2005.04.017_bib5","first-page":"4682","article-title":"ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2005.04.017_bib6","first-page":"379","article-title":"Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues","volume":"77","author":"Butler","year":"1997","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejps.2005.04.017_bib7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0022-3565(25)39459-0","article-title":"Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats","volume":"267","author":"Cossum","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2005.04.017_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1566524043360375","article-title":"Antisense strategies","volume":"5","author":"Crooke","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejps.2005.04.017_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0020-708X(84)90196-0","article-title":"Whole-body autoradiography using 11C with double-tracer applications","volume":"35","author":"d\u2019Argy","year":"1984","journal-title":"Int. J. Appl. Radiat. Isot."},{"key":"10.1016\/j.ejps.2005.04.017_bib10","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1038\/sj.onc.1207231","article-title":"Antisense oligonucleotide-based therapeutics for cancer","volume":"22","author":"Dean","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejps.2005.04.017_bib11","first-page":"163","article-title":"Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides","volume":"42","author":"Detrick","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2005.04.017_bib12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0969-8051(02)00345-1","article-title":"Accelerating drug discovery and development through in vivo imaging","volume":"29","author":"Eckelman","year":"2002","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejps.2005.04.017_bib13","first-page":"2024","article-title":"Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II","volume":"62","author":"Fluiter","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2005.04.017_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1124\/dmd.31.11.1419","article-title":"Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2\u2032-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species","volume":"31","author":"Geary","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2005.04.017_bib15","first-page":"562","article-title":"Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides","volume":"2","author":"Geary","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2005.04.017_bib16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"3","author":"Geary","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2005.04.017_bib17","first-page":"383","article-title":"Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides","volume":"12","author":"Geary","year":"1997","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.ejps.2005.04.017_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/oli.1.1998.8.43","article-title":"Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion","volume":"8","author":"Grindel","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.ejps.2005.04.017_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/019262339902700117","article-title":"Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1","volume":"27","author":"Henry","year":"1999","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejps.2005.04.017_bib20","first-page":"2306","article-title":"Technetium-99m labeling of DNA oligonucleotides","volume":"36","author":"Hnatowich","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2005.04.017_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/BF00843711","article-title":"The imaging science of positron emission tomography","volume":"23","author":"Jones","year":"1996","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.ejps.2005.04.017_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6","article-title":"Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes","volume":"80","author":"Kita","year":"1999","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ejps.2005.04.017_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03165654","article-title":"Visualization of the bone\/bone marrow of lower extremities in Ga-67 whole-body images","volume":"4","author":"Koizumi","year":"1990","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.ejps.2005.04.017_bib24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/bc990183i","article-title":"General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies","volume":"11","author":"K\u00fchnast","year":"2000","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2005.04.017_bib25","first-page":"205","article-title":"Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated \u2019knock-down\u2019 of the mouse delta opioid receptor in vitro and in vivo","volume":"213","author":"Lai","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejps.2005.04.017_bib26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3891\/acta.chem.scand.53-0651","article-title":"Compounds labelled with short-lived beta(+)-emitting radionuclides and some applications in life sciences. The importance of time as a parameter","volume":"53","author":"L\u00e5ngstr\u00f6m","year":"1999","journal-title":"Acta Chem. Scand."},{"key":"10.1016\/j.ejps.2005.04.017_bib27","first-page":"37","article-title":"Is PET a tool for drug evaluation?","volume":"volume 26","author":"L\u00e5ngstr\u00f6m","year":"1995"},{"key":"10.1016\/j.ejps.2005.04.017_bib28","first-page":"2891","article-title":"Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin","volume":"6","author":"Lopes de Menezes","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2005.04.017_bib29","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1088\/0031-9155\/47\/19\/306","article-title":"Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET","volume":"47","author":"Lubberink","year":"2002","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.ejps.2005.04.017_bib30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.280.10.871-JMN0909-6-1","article-title":"First \u201cantisense\u201d drug will treat CMV retinitis","volume":"280","author":"Marwick","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejps.2005.04.017_bib31","doi-asserted-by":"crossref","first-page":"19954","DOI":"10.1016\/S0021-9258(19)88650-7","article-title":"Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides","volume":"267","author":"Monia","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2005.04.017_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/oli.1.2000.10.423","article-title":"Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit","volume":"10","author":"Nesterova","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.ejps.2005.04.017_bib33","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ki.1995.406","article-title":"Renal uptake of an 18-mer phosphorothioate oligonucleotide","volume":"48","author":"Oberbauer","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejps.2005.04.017_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrd837","article-title":"Nucleic-acid therapeutics: basic principles and recent applications","volume":"1","author":"Opalinska","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2005.04.017_bib35","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2174\/1381612003398906","article-title":"Positron emission tomography in drug development and drug evaluation","volume":"6","author":"Paans","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2005.04.017_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00003495-200060020-00001","article-title":"The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease","volume":"60","author":"Phillips","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2005.04.017_bib37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0006-2952(97)00190-1","article-title":"Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration","volume":"54","author":"Phillips","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2005.04.017_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)36594-2","article-title":"Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice","volume":"281","author":"Raynaud","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2005.04.017_bib39","first-page":"347","article-title":"68Ga-labeled oligonucleotides for in vivo imaging with PET","volume":"45","author":"Roivainen","year":"2004","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2005.04.017_bib40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0026-895X(25)10208-3","article-title":"Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate","volume":"45","author":"Sands","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2005.04.017_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/ard.1994.4.99","article-title":"In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice","volume":"4","author":"Sarmiento","year":"1994","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.ejps.2005.04.017_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/sj.bjc.6600416","article-title":"Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor","volume":"87","author":"Shi","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2005.04.017_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1015133205457","article-title":"Characterization of a synthetic anionic vector for oligonucleotide delivery using in vivo whole body dynamic imaging","volume":"4","author":"Tavitian","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2005.04.017_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0498-467","article-title":"In vivo imaging of oligonucleotides with positron emission tomography","volume":"4","author":"Tavitian","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2005.04.017_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jlcr.799","article-title":"Microwave accelerated Ga-68-labelling of oligonucleotides","volume":"47","author":"Velikyan","year":"2004","journal-title":"J. Label. Compd. Rad."},{"key":"10.1016\/j.ejps.2005.04.017_bib46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1021\/bc030078f","article-title":"Microwave-supported preparation of Ga-68 bioconjugates with high specific radioactivity","volume":"15","author":"Velikyan","year":"2004","journal-title":"Bioconj. Chem."},{"key":"10.1016\/j.ejps.2005.04.017_bib47","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2005.04.017_bib48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.nucmedbio.2004.06.006","article-title":"Hybridisation of [76Br]-labelled antisense oligonucleotides to Chromogranin A mRNA verified by RT-PCR","volume":"31","author":"Wu","year":"2004","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejps.2005.04.017_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0928-0987(00)00067-1","article-title":"Distribution of (76)Br-labeled antisense oligonucleotides of different length determined ex vivo in rats","volume":"10","author":"Wu","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2005.04.017_bib50","first-page":"1777","article-title":"Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene","volume":"21","author":"Yang","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejps.2005.04.017_bib51","unstructured":"Yngve, U., 2001. Labelling of various macromolecules using positron emitting 76Br and 68Ga. Synthesis and Characterisation. Acta Universitatis Upsaliensis, Comprehensive summaries of Uppsala Dissertations from the Faculty of Science and Technology 605, Uppsala, ISBN 91-554-4939-5."},{"key":"10.1016\/j.ejps.2005.04.017_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3891\/acta.chem.scand.53-0508","article-title":"Synthesis of N-succinimidyl 4-(76Br)bromobenzoate and its use in conjugation labelling of macromolecules","volume":"53","author":"Yngve","year":"1999","journal-title":"Acta Chem. Scand."},{"key":"10.1016\/j.ejps.2005.04.017_bib53","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/nar\/gkh516","article-title":"2\u2032-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro","volume":"32","author":"Yoo","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2005.04.017_bib54","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2174\/1381612023394467","article-title":"Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives","volume":"8","author":"Younes","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2005.04.017_bib55","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2005.04.017_bib56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0006-2952(95)00010-W","article-title":"Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1","volume":"49","author":"Zhang","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2005.04.017_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/oli.1.1998.8.451","article-title":"Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice","volume":"8","author":"Zhao","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098705001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098705001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:43:07Z","timestamp":1760528587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098705001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0928098705001235"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2005.04.017","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2\u2032-O-methyl phosphodiester oligonucleotides in normal rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2005.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}